GMTX insider filings

Gemini Therapeutics, Inc. /DE — 36 most recent insider filings (SEC Forms 3/4/5) from EDGAR, normalized by FilingPulse. Latest filing: 2022-10-27. Screen GMTX transaction legs live →

Insider transaction summary — last 90 days

No insider filings (Forms 3/4/5) for GMTX between 2026-08-23 and 2026-11-21. The table below lists the most recent filings on record.

Recent insider filings — Gemini Therapeutics, Inc. /DE

FiledFormInsiderReported transactionsSource
2022-10-274Leonard Braden Michael — 10% ownerSale (S): 22,500 @ $2.09EDGAR
2022-06-024Piekos Brian — CFOGrant/award (A): 9,960 @ $1.09EDGAR
2022-04-134Leonard Braden Michael — 10% ownerPurchase (P): 55,000 @ $1.36 · Purchase (P): 504,487 @ $1.35 · Purchase (P): 203,744 @ $1.42 · Purchase (P): 191,769 @ $1.52EDGAR
2022-03-094/AOng Tuyen — DirectorGrant/award (A): 15,528 (derivative) @ $0EDGAR
2022-03-094/ALubner David Charles — DirectorGrant/award (A): 17,529 (derivative) @ $0EDGAR
2022-03-094/ALubner David Charles — DirectorGrant/award (A): 0 (derivative) @ $0EDGAR
2022-01-144Piekos Brian — CFOGrant/award (A): 280,876 (derivative) @ $0EDGAR
2022-01-054Meyenburg Jason Patrick — Chief Executive Officer, DirectorGrant/award (A): 123,600 (derivative) @ $0EDGAR
2022-01-054GEMAYEL GEORGES — Executive Chair of the Board, DirectorGrant/award (A): 793,274 (derivative) @ $0EDGAR
2021-11-164GEMAYEL GEORGES — See Remarks, DirectorGrant/award (A): 23,514 (derivative) @ $0 · Grant/award (A): 17,245 (derivative) @ $0EDGAR
2021-10-204Piekos Brian — Chief Financial OfficerGrant/award (A): 90,720 (derivative) @ $0EDGAR
2021-10-064Ong Tuyen — DirectorGrant/award (A): 17,245 (derivative) @ $0EDGAR
2021-10-064Tananbaum James B. — Director, 10% ownerGrant/award (A): 17,245 (derivative) @ $0EDGAR
2021-10-064Rhodes Jason P — Director, 10% ownerGrant/award (A): 17,245 (derivative) @ $0EDGAR
2021-10-064Lubner David Charles — DirectorGrant/award (A): 17,245 (derivative) @ $0EDGAR
2021-10-064GORDON CARL L — Director, 10% ownerGrant/award (A): 17,245 (derivative) @ $0EDGAR
2021-05-184Piekos Brian — Chief Financial OfficerPurchase (P): 7,655 @ $9.46EDGAR
2021-05-184Meyenburg Jason Patrick — President & CEO, DirectorPurchase (P): 13,000 @ $9.46EDGAR
2021-05-034Strapps Walter — Chief Scientific OfficerGrant/award (A): 9,000 (derivative) @ $0EDGAR
2021-05-034GEMAYEL GEORGES — DirectorGrant/award (A): 45,466 (derivative) @ $0EDGAR
2021-04-144Piekos Brian — Chief Financial OfficerGrant/award (A): 377,734 (derivative) @ $0EDGAR
2021-04-144Barone Samuel B. — Chief Medical OfficerGrant/award (A): 255,212 (derivative) @ $0EDGAR
2021-04-074Strapps Walter — Chief Scientific OfficerGrant/award (A): 79,094 (derivative) @ $0EDGAR
2021-04-074Uknis Marc — Chief Medical OfficerGrant/award (A): 277,117 (derivative) @ $0EDGAR
2021-04-074Redmond Precillia — Chief People OfficerGrant/award (A): 77,450 (derivative) @ $0EDGAR
2021-04-074Lauder Scott — Chief Technology OfficerGrant/award (A): 243,996 (derivative) @ $0EDGAR
2021-04-074Meyenburg Jason Patrick — President & CEO, DirectorGrant/award (A): 1,124,832 (derivative) @ $0EDGAR
2021-04-074Ong Tuyen — DirectorGrant/award (A): 58,855 (derivative) @ $0EDGAR
2021-04-074Lubner David Charles — DirectorGrant/award (A): 58,855 (derivative) @ $0EDGAR
2021-03-154Ong Tuyen — DirectorGrant/award (A): 15,000 (derivative) @ $0EDGAR
2021-03-154Lubner David Charles — DirectorGrant/award (A): 25,000 (derivative) @ $0EDGAR
2021-03-034Strapps Walter — Chief Scientific OfficerGrant/award (A): 99,133 (derivative) @ $0EDGAR
2021-02-254Redmond Precillia — Chief People OfficerGrant/award (A): 25,489 (derivative) @ $0EDGAR
2021-02-254Lauder Scott — Chief Technology OfficerGrant/award (A): 272,615 (derivative) @ $0EDGAR
2021-02-094FS Development Holdings, LLC — 10% owner
Foresite Capital Fund V, L.P. — 10% owner
Foresite Capital Management V, LLC — 10% owner
Foresite Capital Opportunity Fund V, L.P. — 10% owner
Foresite Capital Opportunity Management V, LLC — 10% owner
Grant/award (A): 1,500,000 @ $10 · Conversion (C): 2,928,750 @ $0 · Conversion (C): 2,928,750 (derivative) @ $0EDGAR
2021-02-094Tananbaum James B. — DirectorGrant/award (A): 1,500,000 @ $10 · Conversion (C): 2,928,750 @ $0 · Conversion (C): 2,928,750 (derivative) @ $0EDGAR

Recent 8-K events — Gemini Therapeutics, Inc. /DE

Items classified from EDGAR index headers. Browse recent 8-K filings market-wide, by item code →

FiledFormItems reportedSource
2026-11-058-K2.02 — Results of Operations and Financial Condition
9.01 — Financial Statements and Exhibits
EDGAR
2026-10-228-K1.01 — Entry into a Material Definitive Agreement
2.02 — Results of Operations and Financial Condition
8.01 — Other Events
9.01 — Financial Statements and Exhibits
EDGAR
2026-10-198-K7.01 — Regulation FD Disclosure
8.01 — Other Events
9.01 — Financial Statements and Exhibits
EDGAR
2026-09-108-K7.01 — Regulation FD Disclosure
8.01 — Other Events
9.01 — Financial Statements and Exhibits
EDGAR
2026-07-308-K2.02 — Results of Operations and Financial Condition
9.01 — Financial Statements and Exhibits
EDGAR
2026-06-308-K1.01 — Entry into a Material Definitive Agreement
2.03 — Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
EDGAR
2026-06-248-K5.07 — Submission of Matters to a Vote of Security HoldersEDGAR
2026-05-058-K2.02 — Results of Operations and Financial Condition
9.01 — Financial Statements and Exhibits
EDGAR
2026-02-278-K?EDGAR
2026-02-268-K2.02 — Results of Operations and Financial Condition
9.01 — Financial Statements and Exhibits
EDGAR
Need this as JSON? GET https://api.filingpulse.io/v1/insider-trades?ticker=GMTX returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. Get a free API key → · API docs